Marker Therapeutics
MRKR
30 hedge funds and large institutions have $1.41M invested in Marker Therapeutics in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 18 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
0.89% less ownership
Funds ownership: 23.39% → 22.5% (-0.89%)
36% less funds holding
Funds holding: 47 → 30 (-17)
73% less capital invested
Capital invested by funds: $5.24M → $1.41M (-$3.83M)
89% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAM
AR Asset Management
West Hollywood,
California
|
+$96.8K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$41.9K |
| 3 |
Millennium Management
New York
|
+$32.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$12.4K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$9.89K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IA
IFP Advisors
Tampa,
Florida
|
-$30K |
| 2 |
MLIC
Mandatum Life Insurance Company
Helsinki,
Finland
|
-$26K |
| 3 |
BlackRock
New York
|
-$25.8K |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$25K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$23.5K |
MRKR Hedge Fund Activity: Q1 2023 in Review
30 of the 6,285 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q1 2023, worth a combined $1.41M — down 73% from $5.24M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of MRKR and 2 opened new positions — a net loss of 16 holders — while 9 trimmed existing stakes and 11 added.
The largest buyer was AR Asset Management, opening a new position worth an estimated $96.8K. The largest seller was IFP Advisors, exiting entirely with an estimated $30K sold.
- 30 institutional investors held Marker Therapeutics (MRKR) as of Q1 2023, down from 47 in Q4 2022.
- Funds reported $1.41M of Marker Therapeutics stock for Q1 2023, down 73% quarter-over-quarter.
- 2 funds opened new Marker Therapeutics positions in Q1 2023 and 18 closed out, a net change of -16 holders.
- The largest Marker Therapeutics buyer in Q1 2023 was AR Asset Management, an estimated $96.8K added.
- The largest Marker Therapeutics seller in Q1 2023 was IFP Advisors, an estimated $30K sold.
Based on aggregated 13F filings for Q1 2023.